1512 related articles for article (PubMed ID: 25652178)
21. The Hippo-YAP pathway: new connections between regulation of organ size and cancer.
Zhao B; Lei QY; Guan KL
Curr Opin Cell Biol; 2008 Dec; 20(6):638-46. PubMed ID: 18955139
[TBL] [Abstract][Full Text] [Related]
22. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
Yan L; Cai Q; Xu Y
Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
[TBL] [Abstract][Full Text] [Related]
23. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
Garcia K; Gingras AC; Harvey KF; Tanas MR
Trends Cancer; 2022 Dec; 8(12):1033-1045. PubMed ID: 36096997
[TBL] [Abstract][Full Text] [Related]
24. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
[TBL] [Abstract][Full Text] [Related]
25. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
27. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
28. The Hippo pathway in normal development and cancer.
Maugeri-Saccà M; De Maria R
Pharmacol Ther; 2018 Jun; 186():60-72. PubMed ID: 29305295
[TBL] [Abstract][Full Text] [Related]
29. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
30. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
31. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
Budel SJ; Penning MM; Penning LC
Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
[TBL] [Abstract][Full Text] [Related]
32. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
33. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
34. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
35. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
[TBL] [Abstract][Full Text] [Related]
37. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
38. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
39. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
[TBL] [Abstract][Full Text] [Related]
40. The novel role of Hippo-YAP/TAZ in immunity at the mammalian maternal-fetal interface: Opportunities, challenges.
Huang Z; Zhou J; Leung WT; Gober HJ; Pan X; Li C; Li L; Wang L
Biomed Pharmacother; 2020 Jun; 126():110061. PubMed ID: 32145593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
